Huseni et al. determined that interleukin 6 (IL-6) is associated with poor reaction to atezolizumab (anti-PD-L1) in large clinical trials of advanced renal cancer, breast cancer, and bladder cancer [57]. This evidence concerns the gene IL6 and urinary bladder carcinoma.